Tags : Top

Insights+ COVID-19 Deals (Part I): Biopharma Drug Development

The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at an unprecedented speed to develop vaccines, treatments, and tests.  This article covers last four months of deal data provided by Chris Dokomajilar of DealForma. During the last four months […]Read More

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a […]Read More

Top 20 Biopharma Acquisitions of 2018 Based on the Total

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology, neuroscience, oncology, rare diseases, and plasma-derived therapies. This article is based on the 2018 […]Read More

Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue

The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology, Hematology and multiple diseases but due to a drastic increase in the immune disorders, Immunology segment has been widely spared across the globe. In the top 20 […]Read More

Top 20 Diagnostics Companies Based On 2018 Revenue

With the era of growing diseases, Diagnostics have played a vital role in diagnosing multiple diseases and disorders. The healthcare system is changing, with a greater focus on value, reducing errors and giving more cost-effective care and treatments. The Diagnostic ledger has not changed much in comparison to 2017. Roche Diagnostics holds to be at […]Read More

Top 20 Medical Device Companies Based on 2018 Revenue

The Medical device market is growing with greater needs of patients and with their emerging diseases. 2018 has shown major advancement in medical device needs and upgrades with 55 novel drug approvals. The year 2018 has shown a slight change in the ledger of top 20 firms while Medtronic holds its first position with a […]Read More

Top 10 Oncology Companies By 2018 Revenue

The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced, effective, and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top […]Read More

Insights+: Novel Drug Approvals by the US FDA in 2018

1.Janssen’s Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Published: 14 Feb,2018 | Tags: Janssen, Erleada, apalutamide, Receives, FDA, Approval, Non-Metastatic Castration-Resistant Prostate Cancer, NM-CRPC 2. Helsinn’s (fosnetupitant + palonosetron) Receives FDA Approval for Managing Chemotherapy-Induced Nausea and Vomiting (CINV) Published: 14 Feb,2018 | Tags: Helsins, fosnetupitant + palonosetron, Receives, FDA, Approval, […]Read More

PharmaShots Year in Review: Biosimilars Approvals in 2018

  THE US FDA APPROVALS    1.  Pfizer’s Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for Anemia Published: 15 May, 2018  | Tags: Pfizer, Retacrit, epoetinalfa-epbx, biosimilar, Receives, FDA, Approval, Anemia   2.   Pfizer’s Nivestym (filgrastim-aafi, biosmilar) Receives FDA Approval forNeutropenia   Published: 20 Jul, 2018 | Tags: (filgrastim-aafi approval biosmilar), Neutropenia, Nivestym, Pfizer, Receives, the […]Read More

PharmaShots Year in Review 2018

 PharmaShots Year in Review | Top 10 Pharma News of 2018  1. Celgene to Acquire Juno for its Cellular Immunotherapy & Hematology Portfolio Published: 22 Jan, 2018 | Tags: Celgene,  Acquire, Juno, Cellular, Immunotherapy, Hematology Portfolio 2.  Sanofi to Acquire Bioverativ for its Hemophilia Products Published: 22 Jan, 2018 | Tags: Sanofi, Acquire, Bioverativ, Treat, […]Read More